Evidence map›Paper›PMID 28591717›Full record

ArticleOncotarget2017

Peretinoin, an acyclic retinoid, suppresses steatohepatitis and tumorigenesis by activating autophagy in mice fed an atherogenic high-fat diet.

Hikari Okada, Riuta Takabatake, Masao Honda, Kai Takegoshi, Taro Yamashita, Mikiko Nakamura, Takayoshi Shirasaki, Yoshio Sakai, Tetsuro Shimakami, Naoto Nagata and 3 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Retinoids as anti-cancer agents and their mechanisms of action.American journal of cancer research · 2022
    Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Generic chemoprevention of hepatocellular carcinoma.Annals of the New York Academy of Sciences · 2019
    Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Hikari OkadaDepartment of Gastroenterology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan.
Riuta TakabatakeDepartment of Gastroenterology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan.
Masao HondaDepartment of Gastroenterology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan.
Kai TakegoshiDepartment of Gastroenterology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan.
Taro YamashitaDepartment of Gastroenterology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan.
Mikiko NakamuraDepartment of Gastroenterology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan.
Takayoshi ShirasakiDepartment of Advanced Medical Technology, Kanazawa University Graduate School of Health Medicine, Kanazawa, Japan.
Yoshio SakaiDepartment of Gastroenterology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan.
Tetsuro ShimakamiDepartment of Gastroenterology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan.
Naoto NagataDepartment of Cell Metabolism and Nutrition, Brain/Liver Interface Medicine Research Center, Kanazawa University, Kanazawa, Japan.
Toshinari TakamuraDepartment of Disease Control and Homeostasis, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.
Takuji TanakaThe Tohkai Cytopathology Institute, Cancer Research and Prevention, Gifu, Japan.
Shuichi KanekoDepartment of Gastroenterology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan.
Kanazawa University · JPOkazaki Institute for Integrative Bioscience · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The pathogenesis of non-alcoholic steatohepatitis (NASH) is still unclear and the prevention of the development of hepatocellular carcinoma (HCC) has not been established. We established an atherogenic and high-fat diet mouse model that develops hepatic steatosis, inflammation, fibrosis, and liver tumors at a high frequency. Using two NASH-HCC mouse models, we showed that peretinoin, an acyclic retinoid, significantly improved liver histology and reduced the incidence of liver tumors. Interestingly, we found that peretinoin induced autophagy in the liver of mice, which was characterized by the increased co-localized expression of microtubule-associated protein light chain 3B-II and lysosome-associated membrane protein 2, and increased autophagosome formation and autophagy flux in the liver. These findings were confirmed using primary mouse hepatocytes. Among representative autophagy pathways, the autophagy related (Atg) 5-Atg12-Atg16L1 pathway was impaired; especially, Atg16L1 was repressed at both the mRNA and protein level. Decreased Atg16L1 mRNA expression was also found in the liver of patients with NASH according to disease progression. Promoter analysis revealed that peretinoin activated the promoter of Atg16L1 by increasing the expression of CCAAT/enhancer-binding-protein-alpha. Interestingly, Atg16L1 overexpression in HepG2 cells inhibited palmitate-induced NF-kB activation and interleukin-6-induced STAT3 activation. We showed that Atg16L1 induced the de-phosphorylation of Gp130, a receptor subunit of interleukin-6 family cytokines, which subsequently repressed phosphorylated-STAT3 (Tyr705) levels, and this process might be independent of autophagy function. Thus, peretinoin prevents the progression of NASH and the development of HCC through activating the autophagy pathway by increased Atg16L1 expression, which is an essential regulator of autophagy and anti-inflammatory proteins.

Indexed as

AnimalsAutophagyAutophagy-Related ProteinsCarcinoma, HepatocellularCarrier ProteinsCells, CulturedDiet, AtherogenicDiet, High-FatGene Expression ProfilingHepatocytesHep G2 CellsHumansLiverLiver NeoplasmsMaleMice, Inbred C57BL(2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acidAtg16l1 protein, mouseAutophagy-Related ProteinsCarrier ProteinsRetinoidsacyclic retinoidautophagyhepatocellular carcinoma (HCC)non-alcoholic fatty liver disease (NAFLD)

Identifiers

PMID28591717
PMCPMC5522259
OpenAlexW2618393732

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.